Cognetivity Neurosciences Partners With Clairvo to Advance AI Powered Brain Health Management in Japan
Cognetivity Neurosciences Partners With Clairvo to Advance AI Powered Brain Health Management in Japan
Partnership will accelerate adoption of Cognetivity's AI platform in Japan and other Asia-Pacific territories
合作夥伴關係將加快Cognetivity的人工智慧平臺在日本和其他亞太地區的採用
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), is thrilled to announce a strategic partnership with CLAIRVO TECHNOLOGIES, Inc. (hereinafter, "Clairvo"), a wholly owned subsidiary of Marubeni Corporation (market cap US$ 28bn, TYO: 8002), aimed at revolutionizing brain health and addressing dementia-related challenges in Japan. Leveraging the power of artificial intelligence (AI), this partnership seeks to enhance preventative care and promote healthy aging within the Japanese population. As part of the collaboration, Clairvo, a leading company in medical AI diagnostic imaging products, will join forces with Cognetivity, renowned for its novel technology and testing platform CognICA. Together, they aim to integrate CognICA into Clairvo's existing AI portfolio of health and wellness products, providing innovative cognitive monitoring capabilities to the Japanese population.
溫哥華,不列顛哥倫比亞省-(Newsfile Corp.-2023年6月13日)-認知神經科學有限公司。(CSE:CGN)(OTCQB:CGNSF)(FSE:1UB)(“公司”或“認知性”),非常高興地宣佈與丸紅株式會社(市值280億美元,TYO:8002)的全資子公司CLAIRVO Technologies,Inc.(以下簡稱“Clairvo”)建立戰略合作夥伴關係,旨在為日本的大腦健康和應對痴呆症相關挑戰帶來革命性的變化。利用人工智慧(AI)的力量,這一合作夥伴關係旨在加強預防性護理,促進日本人口的健康老齡化。作為合作的一部分,醫療人工智慧診斷成像產品領域的領先公司Clairvo將與以新技術和測試平臺CognICA聞名的Cognetivity聯手。他們的共同目標是將CognICA整合到Clairvo現有的AI健康和健康產品組合中,為日本人口提供創新的認知監測能力。
Dementia and cognitive decline have become a global healthcare challenge particularly in Japan where the aging population is on the rise. By harnessing the potential of AI and cognitive assessment technologies, Clairvo and Cognetivity aim to empower individuals and healthcare professionals in early detection and continuous monitoring of cognitive health. This proactive approach will enhance the benefits of early intervention and personalized care, ultimately promoting brain health, well-being, and improved quality of life. Earlier this year the US Food and Drug Administration (FDA) approved Lecanemab, a breakthrough drug to treat Alzheimer's, manufactured by Eisai Co Ltd (TYO: 4523) a Japanese biopharmaceutical company, which requires early diagnosis to be effective.
痴呆症和認知能力下降已成為全球醫療保健領域的挑戰,尤其是在人口老齡化呈上升趨勢的日本。通過利用人工智慧和認知評估技術的潛力,Clairvo和Cognetivity旨在使個人和醫療保健專業人員能夠及早發現和持續監測認知健康。這種積極主動的方法將加強早期幹預和個性化護理的好處,最終促進大腦健康、福祉和改善生活品質。今年早些時候,美國食品和藥物管理局(FDA)批准了Lecanemab,這是一種治療阿爾茨海默氏症的突破性藥物,由日本生物製藥公司衛材有限公司(TYO:4523)生產,需要早期診斷才能有效。
Clairvo Technologies is a major player in the medical device industry and is committed to providing innovative solutions that enhance patient care and contribute to better health outcomes. Clairvo sources world-leading AI driven medical technologies with strong validation to accelerate their adoption in Japan.
Clairvo Technologies是醫療器械行業的主要參與者,致力於提供創新的解決方案,以加強患者護理並為更好的健康結果做出貢獻。Clairvo為世界領先的人工智慧驅動的醫療技術提供強大的驗證,以加快其在日本的採用。
Dr. Sina Habibi, CEO of Cognetivity Neurosciences, expressed his excitement about the collaboration, stating, "This is another significant development for Cognetivity in Japan, one of the largest and most advanced economies globally. However, Japan is facing a growing aging problem, with over 29% of its population currently aged above 65. We are delighted to be working with our partners across the Japanese healthcare systems from payers to providers and technology suppliers to tackle this public health crisis and give the elderly population a brighter and healthier life. CognICATM will enable wide scale population screening and provide access to the incoming treatments at earlier stages when they are most effective. Our AI platform enables clinicians to make more informed decisions when diagnosing, monitoring, and treating patients at the provider level and healthcare managers at population level. Japan can be a role model for the rest of the world and we are extremely excited by the opportunity."
認知神經科學公司首席執行官Sina Habibi博士表達了他對這一合作的興奮之情,他指出,這是日本認知公司的又一項重大發展,日本是全球最大和最發達的經濟體之一。然而,日本正面臨著日益嚴重的老齡化問題,目前超過29%的人口年齡在65歲以上。我們很高興能與日本醫療保健系統的合作夥伴合作,從支付者到提供者和技術供應商,共同應對這一公共健康危機,為老年人口提供更光明、更健康的生活。TM將能夠進行大規模的人群篩查,並在最有效的早期階段提供進入治療的機會。我們的人工智慧平臺使臨床醫生在提供者層面診斷、監測和治療患者以及在人群層面的醫療保健經理時能夠做出更明智的決定。日本可以成為世界其他地區的榜樣,我們對這個機會感到非常興奮。“
Mr. Riichi Yamada, President and CEO of Clairvo Technologies, added, "We are thrilled to join forces with Cognetivity Neurosciences, a leader in cognitive assessment technology. This collaboration aligns perfectly with our commitment to introducing innovative AI solutions that improve healthcare outcomes. By incorporating Cognetivity's cutting-edge cognitive assessment platform into our offerings, we aim to provide healthcare professionals in Japan with a powerful tool to enhance cognitive health management and support early interventions."
克萊沃科技首席執行官兼首席執行官山田理一先生補充說:“我們很高興能與認知評估技術的領先者--認知神經科學攜手合作。這一合作與我們推出創新的人工智慧解決方案以改善醫療保健結果的承諾完全一致。通過將認知神經科學的尖端認知評估平臺整合到我們的產品中,我們旨在為日本的醫療專業人員提供一個強大的工具,以加強認知健康管理並支持早期幹預。”
About Cognetivity Neurosciences
關於認知神經科學
Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Cognetivity's CognICATM uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe, and the Middle East, with regulatory approval in other regions expected in 2023.
Cognetivity是一家技術公司,它開發了一種認知測試平臺,用於醫療、商業和消費環境。Cognetivity的CognICATM使用人工智慧和機器學習技術來測試大腦大片區域的性能,以幫助檢測認知功能障礙的早期跡象。CognICA目前可在美國、英國、歐洲和中東用於臨床,預計2023年將在其他地區獲得監管批准。
On behalf of the Board of Directors
我謹代表董事會
"Sina Habibi"
Sina Habibi
《新浪哈比比》
新浪哈比比
Chief Executive Officer and Director
董事首席執行官兼首席執行官
Forward-looking statements:
前瞻性陳述:
Certain statements contained in this news release, including those identified by the words "anticipate," "assume," "believe," "plan," "estimate," "expect," "intend," "may," "should" and similar expressions, to the extent they relate to the Company or its management, constitute forward-looking information or statements (collectively, the "Forward-Looking Statements"). These forward-looking statements are not historical facts and reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions, and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on a number of assumptions regarding our current and future business strategies and the environment in which we operate. We assume no responsibility to update or revise forward-looking information to reflect new events or circumstances, except as required by law. Readers are cautioned not to place undue reliance on our forward-looking statements.
本新聞稿中包含的某些陳述,包括“預期”、“假設”、“相信”、“計劃”、“估計”、“預期”、“打算”、“可能”、“應該”以及類似的表述,在與公司或其管理層有關的範圍內,構成前瞻性資訊或陳述(統稱為“前瞻性陳述”)。這些前瞻性陳述不是歷史事實,反映了對未來結果或事件的當前預期。本新聞稿包含前瞻性陳述。這些前瞻性陳述不是對未來業績的保證,涉及難以預測的風險、不確定性和假設。此類陳述基於當前預期和各種估計、因素和假設,涉及已知和未知的風險、不確定性和其他因素。這些陳述和資訊是基於對我們當前和未來的業務戰略以及我們所處的經營環境的一些假設。除法律要求外,我們不承擔更新或修改前瞻性資訊以反映新事件或新情況的責任。告誡讀者不要過度依賴我們的前瞻性陳述。
The Canadian Securities Exchange is not responsible for the adequacy or accuracy of this release.
加拿大證券交易所不對本新聞稿的充分性或準確性負責。
For more information, please visit: website: or contact: info@cognetivity.com; media inquiries can be sent to pr@cognetivity.com.
欲瞭解更多資訊,請訪問網站:或聯繫方式:info@cognetivity.com;媒體查詢可發送至pr@cognetivity.com。
To view the source version of this press release, please visit
要查看本新聞稿的源版本,請訪問